koral shah, md
@kor_shah
Fellow at City of Hope | Huge fan of @WashuIMRes @UMKCmedschool | Hematology oncology and throwing clay❤️🔥 She/her.
Come visit! 🧬 💉
Koral Shah, MD, (@kor_shah), presents a pilot trial of neoantigen DNA vaccine in combination with nivolumab/ipilimumab and prostvac in metastatic hormone-sensitive prostate cancer (mHSPC) poster (#47) at 1:15pm at McCormick Place in Hall A. #ASCO22 ow.ly/vFrH50Jpzi5
Amazing! Congrats @YuWeiChenMD @kor_shah and to my “niece” Ruchi, whom I know since 2013 when she was a little girl, but I knew she is brilliant! Way to go to help us conquer cancer! @neerajaiims @montypal @kidneycan @TiansterZhang @DrChoueiri @DrRanaMcKay @PavlosMsaouel
Celebrating the winners of the KCRS25 Merit Awards for Clinical Research! 👏 Dr. Yu-wei Chen, University of California San Diego 👏 Dr. Koral Shah, City of Hope 👏 Ruchi Agarwal, University of Pennsylvania #KCRS25 #AcceleratingCures
That's a wrap on #KCRS25! Thank you to everyone who joined us, whether you were with us in Boston or tuning in virtually from around the world. Your presence, questions, and passion for collaboration made this year’s summit one to remember. Until next time, keep pushing the…
Celebrating the winners of the KCRS25 Merit Awards for Clinical Research! 👏 Dr. Yu-wei Chen, University of California San Diego 👏 Dr. Koral Shah, City of Hope 👏 Ruchi Agarwal, University of Pennsylvania #KCRS25 #AcceleratingCures
Excellent insights as always from @montypal on industry support for rare subtype trials. We need more champions like him to push boundaries in #KidneyCancer research. @kidneycan @IKCCorg @advocatekidneys @DrChoueiri @HHammersMD @OncoAlert @NazliDizman @yekeduz_emre @AlbigesL…
Many thanks to @NaomiHaas5 @PennCancer for discussing @WesleyYipMD @cityofhope's adjuvant trial of pembro + #CBM588 - the subject of his @ASCO CDA! Terrific session at #KCRS25.
What an incredible slide from @VincentWenxinXu at #KCRS2025 depicting some of the individuals that have contributed to biomarker research in RCC 🔬. “Biomarkers are a lot of work, but they will reduce both overtreatment and undertreatment” @kidneycan @OncoAlert
#KCRS25 Session 4 featured rapid-fire insights from researchers around the globe, highlighting early data and fresh perspectives that may shape the next wave of kidney cancer research. Quality of Life in Belzutifan vs. Everolimus with @tompowles1 Patient Experience Across the…
Ivonescimab in ccRCC Presented by @NazliDizman at #KCRS25. Targeting tumor microenvironment with cooperative inhibition. Promising concept, eager for results! @kidneycan @IKCCorg @advocatekidneys @DrChoueiri @HHammersMD @OncoAlert @montypal @yekeduz_emre @AlbigesL @MikeSerzanMD…
🌟Happening now at #KCRS25!! Great talk by @kor_shah on exploring health-related quality of life across the RCC spectrum through a conceptual domain analysis #kidneycancer👇 @kidneycan @OncoAlert @urotoday
🌟 Terrific presentation by @ruchia_upenn at #KCRS25! Highlighted global disparities in clinical trial availability for RCC #kidneycancer👇 @OncoAlert @kidneycan @urotoday
@kor_shah did a stellar presentation on our FKSI-23 measure, developed under the mentorship of @tompowles1 and an outstanding expert panel @montypal @DrChoueiri @AlbigesL @virajmaster @brian_rini @spsutkaMD @ERPlimackMD @ViktorGruenwald #KCRS25
What a wonderful keynote at #KCRS25 from @KimrynRathmell on how to foster growth in #earlycareerinvestigators, with pearls for “young people”, mentors, and institutions alike.
Exciting talk by @BraunMDPhD at #KCRS2025 on not only the feasibility of personalized neoantigen vaccines in #kidneycancer , but also preclinical evidence of T cell response & preliminary promising clinical activity 💉🧬 @kidneycan @urotoday @OncoAlert
⭐️ We acknowledge that positive phase II trials don’t always translate into positive phase III results ⭐️Enrollment is challenging in non-clear cell but can be done! ⭐️Industry support can make phase III trials possible and even help accelerate enrollment
⭐️Kicking off #KCRS25 with an impactful presentation by @montypal on industry support for rare RCC trials👉 Phase 3 trials can be done in non-clear cell RCC and should define standards #kidneycancer @kidneycan @OncoAlert @urotoday
Gut bacteria like Akkermansia, Bifidobacterium, and Ruminococcaceae are linked to better outcomes with immune checkpoint inhibitors (ICIs) in melanoma, RCC, and NSCLC. But disrupt the microbiome with antibiotics? ➡️ Higher resistance ➡️ Shorter survival
#KCRS25 Rapid Abstract: @kor_shah @cityofhope will share new insights into what patients with RCC value most at different stages of disease, and how those priorities shaped the FKSI-23 QoL tool. Read all the abstracts: bit.ly/AbstractsKCRS25 Register: bit.ly/RegisterKCRS25…
🚀 4pm at #KCRS25: Rapid Oral Session w @montypal Featuring: ▪️ @tompowles1 Q-TWiST ▪️ @kor_shah FKSI-23 ▪️ @ChadTangMD MRWS ▪️ @CarolinaAlvesC5 Microbiome ▪️ @ruchia_upenn Global disparities ▪️ #JJones WIRE ▪️ @mzugman Papillary RCC Don’t blink. This one’s fast-paced & packed!
Hats off to @ReginaBarCar who (w @ZeynepZengin @YaleIMed) put together a beautiful overview of #microbiome modulation for the treatment of #solidtumors in @JCO_ASCO. Citing work from innovative #scientists & #trialists in the field like #Routy, #ElKrief, @derosa__lisa, #Zitvogel,…
Congratulations to this year's #WorldGU25 poster winners! We are excited to spotlight our 19 winners at the Poster Session & Welcome Reception at the 2-day CE-accredited conference in Nashville, TN, Aug 21-23. Join us and receive up to 11.75 CE credits. hubs.la/Q03wLfxZ0…
Yesterday, I officially graduated from @cityofhope Hematology/Oncology fellowship program! I truly can’t believe how fast the 3 years flew by. So grateful for the wonderful experience I had during fellowship and the opportunity to work alongside such inspiring mentors. Excited…